Introduction
============

Familial glucocorticoid deficiency (FGD) was reported for the first time by Shepard *et al* ([@b1-mmr-22-02-0681]), in 1959. The study described a case of two sisters who presented adrenal insufficiency, cortisol hormone deficiency and normal levels of aldosterone, renin, skin hyperpigmentation, muscle weakness and other performances. In addition, the serum electrolytes and blood pressure were normal and the cortisol (COR) levels were not affected by the treatment with adrenocorticotropic hormone (ACTH). Hitherto, the identified FGD-related genes were the following: Melanocortin 2 receptor/ACTH receptor (*MC2R*) ([@b2-mmr-22-02-0681]), *MC2R* accessory protein (*MRAP*) ([@b3-mmr-22-02-0681]), nicotinamide nucleotide transhydrogenase (*NNT*) ([@b4-mmr-22-02-0681]), the minichromosome maintenance-deficient 4 homolog gene (*MCM4*) ([@b5-mmr-22-02-0681]), thioredoxin reductase (*TXNRD2*) ([@b6-mmr-22-02-0681]), steroid hormone acute regulatory protein (*STAR*) ([@b7-mmr-22-02-0681]) and cytochrome P450 family 11 subfamily A polypeptide 1 (*CYP11A1*) ([@b8-mmr-22-02-0681]). Of these, *MC2R* and *MRAP* accounted for 50% of all the mutations.

The *STAR* gene encodes a steroid acute regulatory protein that serves a key function in the steroid synthesis. In this process, cholesterol is presented to the cytochrome P450scc encoded by the *CYP11A1* gene, catalyzing the cholesterol to pregnenolone, which regulates the supply of substrate cholesterol from the mitochondrial outer membrane to the underlying mitochondrial membrane. The gene mutation effectuates as early onset and causes severe steroid hormone deficiency, hypoglycemia, loss of salt, dysplasia and adrenal lipid deposition ([@b9-mmr-22-02-0681],[@b10-mmr-22-02-0681]), usually within a few months after birth.

Some non-classical mutations can retain certain features, resulting in FGD clinical manifestations, such as that of the two sibling patients described in this article. Interestingly, they demonstrated the clinical diagnosis as primary adrenal insufficiency (PAI) but with normal gonadal function and adrenal hyperplasia. The c.533T\>A (p. Leu178Gln) and c.737A\>G (p. Asp246Gly) mutations in the *STAR* gene were obtained from the parents and confirmed by the second-generation sub-whole exon gene sequencing.

Case report
===========

### Patient 1

A normal female 34-year-old proband was the first-born child of non-consanguineous parents. The patient was admitted to The First Affiliated Hospital of Zhengzhou University in March 2017 because of skin pigmentation experienced for 32 years, low blood pressure for 6 years and intermittent nausea and vomiting for 6 months. The patient was born in 1982 after an uneventful pregnancy. At the age of two, the patient suffered from upper respiratory tract infection several times and skin hyperpigmentation gradually started to appear. Pubertal development started at the age of 11, menarche was presented at 13 and currently (in 2018), the patient has a 10-year-old son. The patient was diagnosed with 'bipolar affective disorder' 4 years ago and was treated with oral medication such as lithium carbonate, lorazepam, sertraline and buspirone. The karyotype of the patient was 46, XX with skin hyperpigmentation ([Fig. 1A](#f1-mmr-22-02-0681){ref-type="fig"}); however, the breasts and vulva were normal. Blood pressure was 80/40 mmHg, fasting blood glucose was 3.9 (normal range: 3.6--6.1) mmol/l, serum sodium was 126 mmol/l (normal range: 135--155 mmol/l), 17-hydroxyprogesterone (17-OHP) was 0.31 ng/ml, dehydroepiandrosterone (DHEA) was \<15 (normal range: 35--430) µg/dl, normal serum gonadotropin concentrations for follicle stimulating hormone (FSH) and luteinizing hormone (LH) were 5.36 and 5.83 mIU/ml, respectively, the lying position renin-angiotensin-aldosterone system (RAAS) showed that renin activity was \>26.68 (normal range: 0.15--2.33) ng/ml.h, angiotensin II was 232.0 (normal range: 25--80) pg/ml and aldosterone was 153.0 (normal range: 30--160) pg/ml. ACTH-COR rhythm is listed in [Table I](#tI-mmr-22-02-0681){ref-type="table"}. The 24-h urine-free cortisol (UFC) was 83 (normal range: 73--372) nmol/l. The cortisol levels did not respond to the stimulation with ACTH (250 µg intravenous injection in 1 min) ([Table II](#tII-mmr-22-02-0681){ref-type="table"}). Computed tomography (CT) revealed bilateral adrenal glands without hyperplasia and the left side presented calcification ([Fig. 2A](#f2-mmr-22-02-0681){ref-type="fig"}).

### Patient 2

The younger brother of patient 1 was born in 1992 after an uneventful pregnancy. The patient displayed skin hyperpigmentation from childhood and occasional fatigue. The karyotype of the patient was 46, XY. Pubertal development started at the age of 14 years. Skin hyperpigmentation ([Fig. 1B](#f1-mmr-22-02-0681){ref-type="fig"}) by the Tanner staging of testis was 4, and the patient was unmarried. Normal blood glucose, serum electrolytes, serum gonadotropin concentrations: FSH 6.12 (normal range: 0.95--11.95) mIU/ml and LH 4.95 (normal range: 1.14--8.75) mIU/ml, DHEA was 58.2 (normal range: 80--560) µg/dl and lying position RAAS: Renin activity was 22.95 ng/ml.h, angiotensin II was 73.27 pg/ml, aldosterone was 151.7 pg/ml. ACTH-COR rhythm is listed in [Table I](#tI-mmr-22-02-0681){ref-type="table"}; the 24-h UFC was 134 nmol/l. CT did not reveal any hyperplasia in the bilateral adrenal glands ([Fig. 2B](#f2-mmr-22-02-0681){ref-type="fig"}).

Genomic DNA was extracted from the peripheral blood of the two patients and their familial relatives (parents and son of the proband) after written informed consent (the patients agreed to blood sampling, gene testing, publication of their data and figures). Sub-whole exon gene sequencing was performed using Exon Chip Capture (Agilent Technologies, Inc.) and high-throughput sequencing (Beijing Jinzhun Gene Technology Co., Ltd). Sequences of the mutations were aligned against that in the National Center for Biotechnology Information (NCBI) database. The data interpretation was according to the guidelines of the American College of Medical Genetics and Genomics (ACMG) and variations were named according to the recommendations of the Human Genome Variation Society (HGVS; [www.hgvs.org/mutnomen](www.hgvs.org/mutnomen)). The protein was predicted by Polyphen2, Sorting Intolerant From Tolerant (SIFT) and Protein Variation Effect Analyzer (PROVEAN) software and SWISS-MODEL was used to construct the protein model. Alterations in the protein structure and amino acid hydrogen bond were analyzed before and after the mutation.

The patients were treated with oral administration of 20 mg hydrocortisone (HC) in the morning and 10 mg in the evening. Indicators such as skin pigmentation, appetite, blood pressure, ACTH, serum cortisol, serum electrolytes and blood glucose were monitored regularly and the HC dose was changed according to the symptoms and the results of testing.

Two heterozygote mutations c.533T\>A (p. Leu178Gln) and c.737A\>G (p. Asp246Gly) were found on the *STAR* gene in the two patients; one was passed from each parent, respectively, and the son of the proband carried one of the mutations ([Fig. 3](#f3-mmr-22-02-0681){ref-type="fig"}). The sequencing of the peak pattern revealed an additional peak that was further verified by the first generation of gene sequencing ([Fig. 4](#f4-mmr-22-02-0681){ref-type="fig"}). The amino acid sequence alignments revealed that positions 178 and 246 were highly conserved across species ([Fig. 5](#f5-mmr-22-02-0681){ref-type="fig"}). Polyphen2 ([genetics.bwh.harvard.edu/pph2](genetics.bwh.harvard.edu/pph2)), SIFT ([sift.bii.a-star.edu.sg](sift.bii.a-star.edu.sg)) and PROVEAN ([provean.jcvi.org/genome_submit_2.php?species=human](provean.jcvi.org/genome_submit_2.php?species=human)) software predicted the mutations as detrimental ([Table III](#tIII-mmr-22-02-0681){ref-type="table"}). The computational model used in this study was modified by introducing the missense mutations using the Swiss-Model program ([Fig. 6](#f6-mmr-22-02-0681){ref-type="fig"}). The tertiary structure before and after the mutation did not alter; however, Gln178 formed a new hydrogen bond with Gly176 and the hydrogen bond between Asp246 and Lys248 disappeared after mutation. The skin hyperpigmentation ([Fig. 1](#f1-mmr-22-02-0681){ref-type="fig"}) and the general state of the two patients was improved after three months of treatment. They also gained weight. The serum cortisol, serum electrolytes and blood glucose were normal, cortisol increased and ACTH decreased significantly in the proband, while the ACTH level in patient 2 was high in the short-term.

Discussion
==========

The patients included in the present case were siblings, who presented skin hyperpigmentation throughout the body, particularly in hands, lips and nipples. The gonadal development was normal, but laboratory tests suggested glucocorticoid deficiency and mild lack of mineralocorticoid, indicating hyponatremia and hypotension in the proband. The cortisol level was not affected by the stimulation with ACTH and the clinical diagnosis was PAI; however, the adrenal glands did not show any hyperplasia. Gene analysis revealed two novel compound heterozygote mutations c.533T\>A (p. Leu178Gln) and c.737A\>G (p. Asp246Gly) in the *STAR* gene, which were passed onto the patients, one from each parent, respectively.

In 1994, Clark *et al* ([@b11-mmr-22-02-0681]) cloned the complementary DNA for a 30-kDa mouse mitochondrial protein that appeared to be rapidly inducible, cycloheximide-sensitive mediator of the acute steroidogenic response, and termed it STAR. STAR is produced as a 285-amino-acid protein with an N-terminal signal sequence that targets the molecule to the interior of the mitochondria, while the C-terminal STAR-related lipid transfer domain is essential for its function and forms a pocket that might bind cholesterol ([@b12-mmr-22-02-0681],[@b13-mmr-22-02-0681]). All steroids are derived from pregnenolone, a product of the cholesterol side chain cleavage reaction catalyzed by CYP11A ([@b14-mmr-22-02-0681]) and the supply of substrate cholesterol from the outer mitochondrial membrane to this inner mitochondrial membrane enzyme is regulated by STAR. The transfer of cholesterol to P450scc constitutes the rate-limiting step in steroidogenesis. The mutations in the *STAR* gene are primarily concentrated in the C-terminal of the protein encoded by exons 5, 6 and 7, causing congenital lipoid adrenal hyperplasia (CLAH), which is the rarest but most severe form of CAH ([@b15-mmr-22-02-0681]). It results from a general loss of all steroid production and is presented as primary adrenal insufficiency or Addison\'s disease. The symptoms include low body weight, severe dehydration, skin hyperpigmentation, respiratory distress and vomiting in patients.

However, in 2006, Baker *et al* ([@b16-mmr-22-02-0681]) reported that patients with STAR disorder show a late presentation and normal male genitalia, thus are defined as having a new disorder, 'non-classic LCAH' (NCLAH). This phenomenon represented a new cause of non-autoimmune Addison\'s disease (primary adrenal failure). In 2009, Metherell *et al* ([@b7-mmr-22-02-0681]) screened FGD patients from 80 families and revealed homozygous STAR mutations in five families. In addition, the results demonstrated that specific mutations in STAR cause NCLAH masquerading as FGD and present a phenotype indistinguishable from that of FGD. The partial loss-of-function due to STAR mutations was deemed as a cause of type 3 FGD with ≥10 cases of the mutations reported ([@b17-mmr-22-02-0681]).

The study by Baker *et al* ([@b16-mmr-22-02-0681]) described the FGD-like phenotypes in three patients with mutations, V187M and R188C, in adjacent codons. The structural modeling of both residues encompassed within the cholesterol-binding pocket of STAR suggested that the R188C mutation would prevent the formation of a salt bridge typically localized between residues E169 and R188 but could result in a weak bond between residues T167 and R188 that may sufficiently preserve the binding pocket to transport the cholesterol. The functional analysis of both V187M and R188C mutants revealed that \>20% cholesterol binding activity was retained. This residual activity may be ascribed to the cortisol deficiency and mild hyperreninemia in the 2-year-old patients, thereby resembling the patients with FGD. Thus, in the patients of the present study, the mutations Leu178Gln and Asp246Gly, also within the cholesterol-binding pocket of STAR, may exhibit similar mechanisms. The statistical analysis of 10 cases of mutations in the study by Flück *et al* demonstrated a 3--5% retention of the cholesterol binding activity and the maximum age of onset was 58 years ([@b17-mmr-22-02-0681]). The low levels of STAR-independent steroidogenesis and a complete loss of steroidogenesis due to cellular destruction by accumulated lipids formed the two-hit model of LCAH ([@b18-mmr-22-02-0681]). Interestingly, the adrenals of both patients in the present case revealed no hyperplasia and patient 1 had unilateral calcification. Furthermore, a previous study had already speculated that the cirrhotic end stage of previous fat deposition resembled the imaging changes observed during progression from steatosis hepatitis to liver cirrhosis, although a precise mechanism has yet to be elucidated ([@b7-mmr-22-02-0681]).

In summary, two compound heterozygous mutations in the *STAR* gene in two related patients (sister and brother) with isolated glucocorticoid deficiency were reported. Moreover, lack of mineralocorticoid and normal gonadal function was observed. The proband was preparing for her second child; however, proband and her brother\'s adrenal function may be further affected after several years, thereby necessitating regular monitoring.
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![Changes in the skin pigmentation of the two patients before and after treatment. The image with the arrow is compared to the normal individuals and arrow refers to the patient. (A) Patient 1, skin hyperpigmentation is reduced after treatment. (B) Patient 2, skin hyperpigmentation is reduced after treatment.](MMR-22-02-0681-g00){#f1-mmr-22-02-0681}

![Adrenal CT real-time imaging examination of the patients. (A) Patient 1, no hyperplasia in bilateral adrenal glands and the left arrow indicates calcification. (B) Patient 2, no hyperplasia in bilateral adrenal glands.](MMR-22-02-0681-g01){#f2-mmr-22-02-0681}

![Pedigree of the proband\'s family. Circles indicate women and squares indicate men. Black symbol, the patients (II: Patient 1; II: Patient 2). Black spots, mutation carriers (I: Asp246Gly; I: Leu178Gln; III: Asp246Gly) and white symbol, normal. The arrow indicates the presence of proband and all heterozygous genotype.](MMR-22-02-0681-g02){#f3-mmr-22-02-0681}

![The sequencing peak pattern of the mutations verified by the first generation of gene sequencing. The additional peak indicates the heterozygous genotype.](MMR-22-02-0681-g03){#f4-mmr-22-02-0681}

![Amino acid sequence alignments of human and other homologous proteins. The figure represents the partial alignment of STAR sequences of human, chicken, rat, mouse, horse, bovine, sheep and pig around the position of the two mutations (p. Asp246Gly, Leu178Gln), which is denoted by a frame, revealing highly conserved sequences across mammalian species.](MMR-22-02-0681-g04){#f5-mmr-22-02-0681}

![Computational model modified by introducing missense mutations using the Swiss-Model program. (A) The tertiary structure was not altered before and after the mutation, the mutant amino acids p. Asp246Gly, p. Leu178Gln are presented in yellow. (B) Gln178 forms a new hydrogen bond with Gly176 after mutation. (C) The hydrogen bond between Asp246 and Lys248 (D) disappeared after mutation.](MMR-22-02-0681-g05){#f6-mmr-22-02-0681}

###### 

ACTH-COR rhythm of the two patients.

  A, ACTH (pg/ml)                             
  -------------------- ---------- ----------- -----------
  Patient 1            \>1,250    \>1,250     \>1,250
  Patient 2            \>1,250    \>1,250     --
                                              
  **B, COR (ng/ml)**                          
                                              
  **Patient**          **8:00**   **16:00**   **00:00**
                                              
  Patient 1            201        189         151
  Patient 2            312        186         --

ACTH, adrenocorticotropic hormone; COR, cortisol; -, not applicable.

###### 

ACTH stimulation test of patient 1.

  Variable                  0 min   30 min   60 min
  ------------------------- ------- -------- --------
  COR (ng/ml)               246     231      263
  17-OHP (ng/ml)            0.31    1.82     2.05
  DHEA (µg/dl)              \<15    21.7     20.8
  Androstenedione (ng/ml)   \<0.3   0.6      0.5

ACTH, adrenocorticotropic hormone; COR, cortisol; OHP, hydroxyprogesterone; DHEA, dehydroepiandrosterone.

###### 

Results predicted by Polyphen2, SIFT and PROVEAN software.

              Polyphen2                                      SIFT                PROVEAN                       
  ----------- ---------------------------------------------- ------------------- --------- ---------- -------- -------------
  Leu178Gln   0.897 (sensitivity, 0.70; specificity, 0.90)   Probably damaging   0         Damaging   −3.340   Deleterious
  Asp246Gly   0.989 (sensitivity, 0.52; specificity, 0.95)   Probably damaging   0         Damaging   −5.204   Deleterious

SIFT, Sorting Intolerant From Tolerant; PROVEAN, Protein Variation Effect Analyzer.
